RxDoctor Payments Data

Paige Gault, MD

Endocrinology, Diabetes & Metabolism · Spartanburg, SCNPI 1538185806

Payments from drug & device makers

$1,506in general payments, 2019–2025

Across 79 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$807
  • Lilly USA, LLC$210
  • Dexcom, Inc.$80
  • Amgen$67
  • Shire North American Group Inc$49
  • Novo Nordisk$49
  • plus $243 from 12 others

What the payments were for

  • Food & beverage$1,49499%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,506 in reported general payments places this provider in the 35th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

See all endocrinology, diabetes & metabolism providers in South Carolina

Medicare billing

Part B allowed, 2024
$67,540
Medicare patients
321
Services billed
733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$123,867
MounjaroTirzepatide49$66,358
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog64$56,549
ForteoTeriparatide13$55,799
Tresiba Flextouch U-200Insulin Degludec36$53,512
JardianceEmpagliflozin39$43,235
Humulin R U-500 KwikpenInsulin Regular, Human22$42,500
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/725$42,118
Tresiba Flextouch U-100Insulin Degludec51$40,433
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$39,187
FarxigaDapagliflozin Propanediol28$27,085
Novolog FlexpenInsulin Aspart49$22,188
Fiasp FlextouchInsulin Aspart (Niacinamide)16$13,588
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$11,838
SynthroidLevothyroxine Sodium131$10,966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Forteo, Humalog$210$130,36482 claims
Novo NordiskOzempic, Novolog$49$128,778109 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$17$6,405275 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

Other endocrinology, diabetes & metabolism in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →